AI

DeepSeek’s upcoming model could upend AI economics and security, offering frontier capability at a fraction of the cost. Allegations of industrial-scale distillation and a March 2026 release force CIOs, investors, and regulators to decide: chase dramatic savings or insist on stricter governance. Enterprise AI’s strategic and geopolitical stakes just intensified.

Nvidia may unveil an inference focused chip that could slash per query costs and latency by leveraging a Groq licensing deal. If benchmarks hold, AI inference economics and who profits could flip overnight. Regulators, customers and startups will scramble. This could transform AI budgets, competition and roadmaps. Act now today.

Before you install the latest GPUs or toolkits, pause: shiny upgrades often break pipelines, wreck reproducibility, and balloon costs. Learn the hidden compatibility traps, true TCO math, and safe staging tactics that save teams months and six-figure budgets. Click to avoid costly surprises and upgrade only when it truly pays.

National AI centres are quietly remaking global markets, creating guaranteed procurement, pooled GPUs and training pipelines that favor cloud giants and certified partners. Startups gain customers but lose leverage, while vendors must sell compliance. Track procurement templates, not press releases, since control of compute, data rules and contracts decides winners.

When a CEO credits AI for a blockbuster quarter, it’s not PR—it rewrites who pays for compute, who profits, and who becomes a chokepoint. Explore how hyperscalers, chipmakers, memory suppliers, content owners and legal teams are suddenly reshaped, which vendors win or lose, and what companies must do next today.

Amazon’s $50 billion bet on OpenAI could rewrite where AI lives — shifting costs to persistent cloud memory, tilting chips and cloud deals, and forcing enterprises to weigh speed against vendor lock‑in. Read how stateful runtimes, supply-chain moves, and regulatory risk make this deal the industry’s most consequential play yet.

Tempus AI’s quiet pivot—from diagnostics to a multimodal-data, foundation-model supplier—reshapes valuation, attracting pharma deals and software-like revenue. Discover how a $200M AstraZeneca pact, data moats and hidden lab costs could turbocharge returns or trigger sharp reversals. Investors, builders, and hospital buyers: why this story matters now. Read the full analysis.

Block’s decision to replace 4,000 workers with in-house AI tools didn’t just slash payroll — it rewrites fintech’s operating model. Shares popped, vendors race to win procurement, and recruiters, HR, and regulators face a new reality. Read the inside math, risk calculus, and why rivals won’t soon forget this pivot now.